Cyclacel Pharmaceuticals Inc (CYCC)
1.505
-0.10
(-5.94%)
USD |
NASDAQ |
Apr 26, 13:21
Cyclacel Pharmaceuticals Enterprise Value: -1.269M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | -1.269M |
April 24, 2024 | -0.346M |
April 23, 2024 | -1.018M |
April 22, 2024 | -1.071M |
April 19, 2024 | -1.031M |
April 18, 2024 | -0.9391M |
April 17, 2024 | -0.7941M |
April 16, 2024 | -1.176M |
April 15, 2024 | -1.308M |
April 12, 2024 | -1.058M |
April 11, 2024 | -0.8205M |
April 10, 2024 | -0.6755M |
April 09, 2024 | -0.5964M |
April 08, 2024 | -0.5964M |
April 05, 2024 | -0.6096M |
April 04, 2024 | -0.4874M |
April 03, 2024 | -0.4909M |
April 02, 2024 | -0.5832M |
April 01, 2024 | -0.6755M |
March 28, 2024 | -0.5965M |
March 27, 2024 | -0.7941M |
March 26, 2024 | -0.8469M |
March 25, 2024 | -0.5568M |
March 22, 2024 | -0.4936M |
March 21, 2024 | -0.5041M |
Date | Value |
---|---|
March 20, 2024 | -0.412M |
March 19, 2024 | -0.28M |
March 18, 2024 | -0.0691M |
March 15, 2024 | -0.1745M |
March 14, 2024 | -0.0877M |
March 13, 2024 | 0.0364M |
March 12, 2024 | -0.1074M |
March 11, 2024 | -0.0559M |
March 08, 2024 | 0.1023M |
March 07, 2024 | -0.0954M |
March 06, 2024 | -0.2536M |
March 05, 2024 | 0.0364M |
March 04, 2024 | 0.1814M |
March 01, 2024 | 0.4451M |
February 29, 2024 | -0.0032M |
February 28, 2024 | 0.155M |
February 27, 2024 | 0.2078M |
February 26, 2024 | 0.3132M |
February 23, 2024 | 0.1155M |
February 22, 2024 | 0.0891M |
February 21, 2024 | 0.2012M |
February 20, 2024 | 0.4846M |
February 16, 2024 | 0.5362M |
February 15, 2024 | 0.1353M |
February 14, 2024 | 0.0113M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-18.55M
Minimum
Jun 13 2022
43.63M
Maximum
Mar 19 2021
-1.324M
Average
-3.341M
Median
Dec 26 2019
Enterprise Value Benchmarks
Corvus Pharmaceuticals Inc | 45.43M |
Oragenics Inc | 3.172M |
Relmada Therapeutics Inc | 15.32M |
Alpine Immune Sciences Inc | 3.908B |
MAIA Biotechnology Inc | 48.01M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -5.271M |
Revenue (Quarterly) | 0.031M |
Total Expenses (Quarterly) | 5.391M |
EPS Diluted (Quarterly) | -5.90 |
Profit Margin (Quarterly) | -17.00K% |
Earnings Yield | -1.78K% |
Normalized Earnings Yield | -1749.03 |